Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. - Wikidata - awgldk - TriplyDB

Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.

Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.

http://www.wikidata.org/entity/Q37476384

about

Sperm and oocyte communication mechanisms controlling C. elegans fertility Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice.Chaperoning G protein-coupled receptors: from cell biology to therapeutics Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction.Prostacyclin: an inflammatory paradox.Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis.Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders Long Lasting Microvascular Tone Alteration in Rat Offspring Exposed In Utero to Maternal Hyperglycaemia.Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1.Prostacyclin receptor regulation--from transcription to trafficking.An eicosanoid-centric view of atherothrombotic risk factors Risk management profile of etoricoxib: an example of personalized medicine Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation.Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors.Prostanoids in health and disease.Prostacyclin inhibits IFN-gamma-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner.COX-1 and vascular disease.Platelet physiology and antiplatelet agents.Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Endothelial dysfunction and vascular disease - a 30th anniversary update.Identification and Characterization of Novel Microsomal Prostaglandin E Synthase-1 Inhibitors for Analgesia.The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs.Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century.New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling.A Report of a Novel Mutation in Human Prostacyclin Receptor Gene in Patients Affected with Migraine.Study of molecular mechanism of Prostaglandin E1 in inhibiting coronary heart disease.Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats.

P2860

Q24626882-54C2761C-0BD8-434D-9FBF-F85EE58F0F4F Q28534432-8F3DCDA1-03AC-4C4B-A21A-7192D631FB6D Q28539230-2BBF44DA-1915-4271-BCF5-732528D269B6 Q33639514-E8B996ED-4B40-4A29-845B-F6A6C787F7FB Q33927508-17BA617E-7511-4C6D-A7D8-09C83D3B01B0 Q34023606-B07B999D-F4FF-4230-A05E-95BFF1859A93 Q34060673-F5D63BC0-8FD9-4CBF-91C1-A5E3C8002966 Q34075685-62CDDF49-63DE-4CFB-9976-69262449BC92 Q34344390-AE013463-2CBE-4F33-A43B-295D84AB1915 Q34565310-B4918C54-6C2E-4158-9845-9BE1B63C69B6 Q34580278-D1D80BA7-2612-42FB-887F-E1B43225E0CE Q34606153-23B9862D-C8C0-4B44-B020-DFB140C72D29 Q35025863-9F601E01-2FA0-473E-9720-E9A9BFABE89A Q35133592-1682698C-C5EB-4338-A139-5C0AED3CB9E0 Q35172597-3D93A283-C65F-4341-B7C7-E7B8383A6F41 Q35373624-6CCAF5C8-29E6-4BC8-816F-8BD36B147158 Q35376020-C41E2D70-6966-4C0D-A090-CF368C1516B7 Q35829890-64C145E3-56CE-4064-B42E-4272D19EEA0A Q35891454-F09D9823-2094-4B07-A07D-AE47E5B18614 Q36302755-BDE1FA03-D52B-44BA-9DF6-54CA47AE3DC2 Q36824668-47024B9D-9580-4C9C-A5CB-8D3B9A4115C4 Q36952174-5F4D519C-53B8-4B45-B7EE-FA66C5AB5FF3 Q37052864-6C95EF76-55F6-4113-A44E-5C05EB879D80 Q37063800-D93A2C90-A674-478A-9958-4509258C1529 Q37187131-6A3A8214-4A9C-4B73-A36D-F270B9DFF946 Q37214880-8456BE94-FBC5-4A07-9094-E29DB45D8F5F Q37230714-E5AB9537-A7B2-4D1A-B724-747286862396 Q37354582-E9274DBA-A089-4D3E-B290-86743C5BCCAF Q37438481-EA19D357-A7E4-4385-9436-716CA7830C4A Q37530433-A1FD4435-D446-444E-8BCE-A1D1870F0118 Q37807427-6BDBE69D-2A1A-40A5-B474-2A175B70B5CC Q37995534-7FDF8AE3-147E-4CDE-BD07-F8113492FCCE Q38680112-5662889E-A9BC-4E6A-8A87-BE37A5916561 Q38805945-D1EEAD29-50B4-4192-8E2D-967072B9FBF2 Q39399193-BBE3177E-64E2-4C61-B607-965181A7812F Q42039163-1C4F7078-9BB4-4022-BE1A-02006A056247 Q42960908-0C9EF188-C72C-4383-82E2-52B18E91B135 Q43872293-D0588FCA-F824-4E47-9D43-2F4841C4D287 Q45778627-3FD76145-D6F0-4E17-BFD5-28FB64CDFEA1 Q46344494-ADF94C3D-36BD-43EF-B10B-498C7C203CFE

P2860

Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition.

http://www.wikidata.org/entity/Q37476384

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@en

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@nl

type

label

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@en

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@nl

prefLabel

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@en

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@nl

P1433

Q37476384-579AE9B2-0777-4615-987B-9669EC960A04

P1476

Q37476384-E0F88A56-9563-4E2E-87BB-C584C1505EF8

P2093

Q37476384-1010EDE3-0090-4ECF-9266-17F33A0224E5

Q37476384-180233FF-62B4-4F13-B467-17EA7CC9AFD5

Q37476384-1AE95BC8-2EC0-4714-A3C2-80AA7D43A59E

Q37476384-376F8DC0-32C1-490D-8E94-B8ED8D47F3CF

Q37476384-49D2172C-32C2-4E15-8909-4F06F6A611A7

Q37476384-522BC67F-21EF-4CFA-A6AA-447F41C39C84

Q37476384-70752D6B-C61F-4ABC-ABA8-4DC3E2927D61

Q37476384-7169FEC3-32A8-4B4D-93B5-44F4BF52EFA7

Q37476384-7B2269C1-7178-4DD4-9625-A5F3DC97066E

Q37476384-8081FF6C-7743-4723-B9E0-FC0F5BF90750

P2860

Q37476384-04D56586-C5FF-44A0-A293-141EBA9EB3FA

Q37476384-0D6EB2BD-37E9-4907-AD55-34E2BC185104

Q37476384-0F3C2490-4736-4A50-B907-DC31A03EB16C

Q37476384-137DD750-A3EE-4385-B483-9D7D52FFB395

Q37476384-2F0B4957-8215-4905-9BC4-90F959DE525B

Q37476384-3242F802-4E1D-4352-A4D5-C279CB2DAC98

Q37476384-34CDDB0E-2C64-4C75-BE7D-7F9BB33FC128

Q37476384-39D4C47C-0660-440C-A8B2-1C26E7CBC5F0

Q37476384-3FAA459C-86B0-4235-9EC2-9E073B75F368

Q37476384-401C3863-99D5-4489-A1F1-EF2F157E9F31

P304

Q37476384-119C3423-EABE-43D0-96CF-0D1CEAECD6E8

P31

Q37476384-5A17D704-DB81-4C25-9F8F-890BBF0EA7DE

P356

Q37476384-7EDE0746-CCCD-4BD5-8E95-28B8561A6DB9

P433

Q37476384-F3081BA2-68CF-4A72-B3A5-C046244FD7BC

P478

Q37476384-B07EE9EA-A610-41A0-B565-ED7F0CAEDFE8

P50

Q37476384-40BFF12C-9353-46B1-B488-F313462DBA42

Q37476384-93AA0C51-0716-494E-AC4B-28FB98088D35

Q37476384-A4FC1B1F-E0F3-4100-B0AF-D536FEC9C225

Q37476384-E4B2AFF8-14E5-479D-A3B6-64340C93960F

P577

Q37476384-5F244115-7D8A-4F40-A210-59FE48EFED08

P5875

Q37476384-8C47F3B3-EB74-4BF4-B7F7-D90A797B2C4E

P698

Q37476384-491C2E16-0040-437A-8520-F62E0366BDEE

P921

Q37476384-A95B2D43-CF4B-428F-9328-002622E1A001

P932

Q37476384-D29D65AD-064F-4EE9-BD85-71F3943015B7

P356

CIRCRESAHA.107.165936

P1433

Circulation Research

P1476

Acceleration of cardiovascular ...... r cyclooxygenase-2 inhibition.

@en

P2093

Aaron Kaplan

http://www.w3.org/2001/XMLSchema#string

Eric Arehart

http://www.w3.org/2001/XMLSchema#string

Jeremiah Stitham

http://www.w3.org/2001/XMLSchema#string

John Hwa

http://www.w3.org/2001/XMLSchema#string

John Robb

http://www.w3.org/2001/XMLSchema#string

Karen Douville

http://www.w3.org/2001/XMLSchema#string

Kathleen A Martin

http://www.w3.org/2001/XMLSchema#string

Kristina M Fetalvero

http://www.w3.org/2001/XMLSchema#string

Laurie Martel

http://www.w3.org/2001/XMLSchema#string

Richard J Powell

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and expression of a cDNA for the human prostanoid IP receptor

Crystal structure of rhodopsin: A G protein-coupled receptor

Role of prostacyclin in the cardiovascular response to thromboxane A2

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Prostanoid receptors: structures, properties, and functions

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.

Structural organization and chromosomal assignment of the human prostacyclin receptor gene.

P304

986-993

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCRESAHA.107.165936

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Folkert W. Asselbergs

P577

2008-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5527870

http://www.w3.org/2001/XMLSchema#string

P698

18323528

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2793685

http://www.w3.org/2001/XMLSchema#string